表紙
市場調査レポート

OpportunityAnalyzer:移植片対宿主病(GVHD) - 機会分析と予測

OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2023

発行 GlobalData 商品コード 310940
出版日 ページ情報 英文 260 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
OpportunityAnalyzer:移植片対宿主病(GVHD) - 機会分析と予測 OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2023
出版日: 2015年12月01日 ページ情報: 英文 260 Pages
概要

主要6ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国) における移植片対宿主病 (GVHD) の治療薬市場は、2013年の2億9,700万米ドルから、2023年には5億4440万米ドル規模まで拡大し、CAGRで12.84%の増加が予測されています。

当レポートでは、移植片対宿主病 (GVHD) の治療薬市場について調査分析し、疾患の概要、疫学、現在の治療選択肢、アンメットニーズと機会、研究開発戦略、パイプライン評価などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
  • 症状

第4章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 診断された発症件数:造血幹細胞移植 (HSCT)
    • 診断された発症件数:自家HSCT
    • 診断された発症件数:同種異系HSCT
    • 診断された発症件数:急性移植片対宿主病 (aGVHD)
    • 診断された4年有病件数:aGVHD
    • 診断された発症件数:慢性移植片対宿主病 (cGVHD)
    • 診断された5年有病件数:cGVHD
  • 移植片対宿主病 (GVHD) の疫学予測
    • 診断された発症件数:造血幹細胞移植 (HSCT)
    • 診断された発症件数:自家HSCT
    • 診断された発症件数:同種異系HSCT
    • 診断された発症件数:急性移植片対宿主病 (aGVHD)
    • 診断された4年有病件数:aGVHD
    • 診断された発症件数:慢性移植片対宿主病 (cGVHD)
    • 診断された5年有病者数:cGVHD
  • 議論
    • 疫学予測の考察
    • 分析の限界
    • 分析の強み

第5章 現在の治療選択肢

  • 概要
  • 製品プロファイル:主な治療薬
  • 製品プロファイル:オフラベル治療薬

第6章 アンメットニーズと機会

  • 概要
  • 無作為化臨床試験 (RCT) の欠如
  • 臨床試験評価項目に関する不一致
  • 予防対策の最適化
  • 既存/オフラベル治療薬の標準的プロトコルの欠如
  • 毒性を発症する患者に対する治療結果の改善
  • 長期的な有効性を示す治療への要望
  • ステロイド抵抗性aGVHD患者の管理
  • 硬化性cGVHD患者の管理
  • 肺病変を伴う患者の予後の向上

第7章 研究開発 (R&D) 戦略

  • 概要
  • 現在の臨床試験設計
  • 将来の臨床試験設計

第8章 パイプライン評価

  • 概要
  • 臨床開発中の有望薬
  • 革新的な初期段階のアプローチ

第9章 パイプライン/オフラベルの評価分析

  • 主要パイプライン/オフラベル薬の臨床ベンチマーク
  • 主要パイプライン/オフラベル薬の商業ベンチマーク
  • 競合評価
  • 売上の5ヶ年予測
    • 米国
    • EU5ヶ国

第10章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC014EPOA

The main drivers of growth in graft versus host disease over the 2013-2023 forecast period include the increasing numbers of allogeneic hematopoietic stem cell transplants and the increasing use of biologic off-label and marketed therapies in the 6MM.

Sanofi is a key player in the GVHD market with Thymoglobuline and Lemtrada by infiltrating prophylaxis, aGVHD and cGVHD. J&J's Remicade, has gained a significant patent share of the aGVHD patient group, as it is one of the few drugs that are efficient in GVHD with GI involvement. Gaining more and more ground in the treatment management of cGVHD is Roche's Rituxan that GlobalData estimates will be one of the bestselling biologics in GVHD in the US by 2023.

Despite the vast array of available off-label therapies for the treatment and/or prevention of GVHD, very few of these therapies have been tested in large randomized trials. This results in vague treatment recommendations and many patients being enrolled in institutional clinical trials. The only available standard of care is intravenous methylprednisolone that fails to produce a complete response in more than 50% of treated patients. Steroid-refractory subgroups face low prognosis with deteriorating quality of life. Second and third life treatments can vary from country to country but also between different medical institutions in the same country.

The GVHD market was valued at $297.0m across the 6MM in 2013, and is expected to increase to $544.4m in 2023, at a Compound Annual Growth Rate (CAGR) of 12.84%.

Highlights

Key Questions Answered

  • How will the GVHD market landscape change within the 2013-2023 forecast period in the 6MM?
  • What are the most promising late-stage pipeline drugs in GVHD?
  • How do the clinical and commercial attributes of late-stage pipeline therapies compare to one another and against existing treatment options?
  • What are the unmet needs in GVHD treatment management?
  • What needs to change in the GVHD R&D and treatment guidelines settings?

Key Findings

  • High uptake of off-label biologics (Rituxan, Lemtrada, Remicade and Thymoglobuline)
  • No national guidelines are in place
  • GVHD remains a field of highly unattained unmet need
  • No consensus over clinical trial endpoints
  • Regulatory T cells (Tregs) are the focus of the early stage pipeline
  • Huge opportunity exists in the chronic patient segment of GVHD
  • Institutionally funded studies are the core of GVHD treatment management

Scope

  • Overview of GVHD, including epidemiology, etiology, pathophysiology, symptoms and current treatment options
  • Annualized GVHD therapeutics market revenue, annual cost of therapies and forecasts for five years to 2023.
  • Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the GVHD therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including TNF blockers, CD25a blockers, GVHD-specific therapies etc.
  • Analysis of the current and future market competition in the US and five major EU GVHD therapeutics market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies. Insightful review of the key industry drivers, restraints and challenges.

Reasons to buy

The report will enable you to -

  • Identify the unmet needs and remaining opportunities in the GVHD therapeutics market.
  • Develop business strategies by understanding the trends shaping and driving the US and five major EU GVHD therapeutics market.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Assess the clinical and commercial viability of promising pipeline products.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various emerging therapies.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • Drive revenues by understanding the key trends, innovative products and technologies, market and segments likely to impact the US and five major EU GVHD therapeutics market in future.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Classification and Prognosis
  • 3.2. Symptoms

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Diagnosed Incident Cases of HSCTs
    • 4.4.4. Diagnosed Incident Cases of Autologous HSCTs
    • 4.4.5. Diagnosed Incident Cases of Allogeneic HSCTs
    • 4.4.6. Diagnosed Incident Cases of aGVHD
    • 4.4.7. Four-Year Diagnosed Prevalent Cases of aGVHD
    • 4.4.8. Diagnosed Incident Cases of cGVHD
    • 4.4.9. Five-Year Diagnosed Prevalent Cases of cGVHD
  • 4.5. Epidemiological Forecast for GVHD (2013-2023)
    • 4.5.1. Diagnosed Incident Cases of HSCTs
    • 4.5.2. Diagnosed Incident Cases of Autologous HSCTs
    • 4.5.3. Diagnosed Incident Cases of Allogeneic HSCTs
    • 4.5.4. Diagnosed Incident Cases of aGVHD
    • 4.5.5. Four-Year Diagnosed Prevalent Cases of aGVHD
    • 4.5.6. Diagnosed Incident Cases of cGVHD
    • 4.5.7. Five-Year Diagnosed Prevalent Cases of cGVHD
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Current Treatment Options

  • 5.1. Overview
  • 5.2. Product Profiles - Major Therapies
    • 5.2.1. Methylprednisolone (numerous brand and generic names)
    • 5.2.2. Cyclosporine (numerous brands and generic names)
    • 5.2.3. Anti-Thymocyte Globulin (ATG) Therapies
  • 5.3. Product Profiles - Off-Label Therapies
    • 5.3.1. Biologics (Tumor Necrosis Factor (TNF)α Inhibitors, Interleukin-2 Receptor α (CD25) Inhibitors, Co-Stimulatory Blockers and Other Biologics)
    • 5.3.2. Small Immunosuppressive Molecules (mTOR Inhibitors, Solid Organ Transplant Therapies, and Anti-Neoplastic Therapies)

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Lack of Randomized Clinical Trials
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. No Consensus Regarding Clinical Trial Endpoints
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Optimization of Prophylactic Measures
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Lack of Standardized Protocols for Established and Off-Label Therapies
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Improved Treatment Outcomes for Patients Who Develop Toxicities
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Desire for Treatments that Exhibit Longer-Lasting Efficacy Profiles
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity
  • 6.8. Management of SR-aGVHD Patients
    • 6.8.1. Unmet Need
    • 6.8.2. Gap Analysis
    • 6.8.3. Opportunity
  • 6.9. Management of Sclerotic cGVHD Patients
    • 6.9.1. Unmet Need
    • 6.9.2. Gap Analysis
    • 6.9.3. Opportunity
  • 6.10. Improved Prognosis for Patients with Lung Involvement
    • 6.10.1. Unmet Need
    • 6.10.2. Gap Analysis
    • 6.10.3. Opportunity

7. Research and Development Strategies

  • 7.1. Overview
    • 7.1.1. Improvement of Prophylactic Regimens
    • 7.1.2. Inhibition of T-Cell Proliferation and Activation
    • 7.1.3. Adopting Treatments from Hematologic Indications
    • 7.1.4. Targeting Niche Subgroups Within GVHD
  • 7.2. Current Clinical Trial Design
    • 7.2.1. Current Trial Designs are Dependent on the Stage Within the Treatment Algorithm That a Product is Targeting
    • 7.2.2. Lack of Consensus on Clinical Endpoints in Current Trial Designs
    • 7.2.3. Patient Exclusion Issues in Current Trial Designs
    • 7.2.4. Current Trial Design of Key Pipeline Products
  • 7.3. Future Clinical Trial Design
    • 7.3.1. Future Trial Designs Need to Incorporate Randomization
    • 7.3.2. Future Trial Designs Need to Incorporate Conditioning Regimens and Hematological Patients
    • 7.3.3. Companies Behind Off-Label Therapies Should Strategize to Conduct Randomized Studies
    • 7.3.4. Companies with Pipeline Assets Targeting GVHD must invest in Biomarkers
    • 7.3.5. Design of Early-Phase Clinical Trials for Cellular and Gene Therapy Products Accommodates 2014 Guidance from the FDA

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Leukotac (inolimomab)
    • 8.2.2. Begedina (BT 5/9)
    • 8.2.3. Budenofalk (budesonide)
    • 8.2.4. ATG-Fresenius (EZ-2053)
    • 8.2.5. Prochymal (remestemcel-L)
    • 8.2.6. MultiStem (modified mesenchymal stem cells)
    • 8.2.7. Uvadex (Extracorporeal Photophoresis)
    • 8.2.8. orBec (beclomethasone dipropionate)
  • 8.3. Innovative Early-Stage Approaches
    • 8.3.1. Targeting Regulatory T Cells
    • 8.3.2. Mesenchymal Stem Cell Therapies
    • 8.3.3. Immunomodulatory Cell Surface Receptor Inhibitors
    • 8.3.4. IL-6 Inhibitors

9. Pipeline and Off-Label Valuation Analysis

  • 9.1. Clinical Benchmarking of Key Pipeline and Off-Label Drugs
    • 9.1.1. GVHD Prophylaxis
    • 9.1.2. Acute GVHD
    • 9.1.3. Chronic GVHD
  • 9.2. Commercial Benchmarking of Key Pipeline and Off-Label Drugs
    • 9.2.1. GVHD Prophylaxis
    • 9.2.2. Acute GVHD
    • 9.2.3. Chronic GVHD
  • 9.3. Competitive Assessment
    • 9.3.1. GVHD Prophylaxis
    • 9.3.2. Acute GVHD
    • 9.3.3. Chronic GVHD
  • 9.4. Top-Line Ten-Year forecast
    • 9.4.1. US
    • 9.4.2. 5EU

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed GVHD Patients
    • 10.4.2. Percent Drug-Treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
    • 10.4.7. Generic Erosion
    • 10.4.8. Pricing of Pipeline Agents
  • 10.5. Physicians and Specialists Included in This Study
  • 10.6. About the Authors
    • 10.6.1. Author
    • 10.6.2. Reviewer
    • 10.6.3. Epidemiologist
    • 10.6.4. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Steps Involved in the Development of aGVHD
  • Table 2: Steps Involved in the Development of cGVHD
  • Table 3: Grading System of Organ Involvement in aGVHD
  • Table 4: Classification of Organ Involvement in cGVHD
  • Table 5: Symptoms of aGVHD
  • Table 6: Symptoms of cGVHD
  • Table 7: Risk Factors and Comorbidities for GVHD
  • Table 8: 6MM, Sources of HSCT, aGVHD, and cGVHD Data Used for the Forecast
  • Table 9: 6MM, Sources Not Used in the Epidemiological Analysis of GVHD
  • Table 10: 6MM, Diagnosed Incident Cases of HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Table 11: 6MM, Diagnosed Incident Cases of Autologous HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Table 12: 6MM, Diagnosed Incident Cases of Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Table 13: 6MM, Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Table 14: 6MM, Four-Year Diagnosed Prevalent Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023
  • Table 15: 6MM, Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023
  • Table 16: 6MM, Five-Year Diagnosed Prevalent Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023
  • Table 17: Product Profile - Methylprednisolone
  • Table 18: Efficacy of Methylprednisolone in GVHD Studies
  • Table 19: SWOT analysis - Methylprednisolone, 2014
  • Table 20: Product Profile - Cyclosporine
  • Table 21: Efficacy of Cyclosporine in GVHD Studies
  • Table 22: SWOT Analysis - Cyclosporine, 2014
  • Table 23: Product Profiles - ATG Therapies
  • Table 24: Efficacy of ATG Therapies in GVHD
  • Table 25: SWOT Analysis - ATG Therapies, 2014
  • Table 26: Product Profile - Biologics - TNFα Inhibitors
  • Table 27: Efficacy of Anti-TNFα Therapies in GVHD
  • Table 28: Product Profiles - Biologics - IL-2Rα (CD25) Inhibitors
  • Table 29: Efficacy of IL-2Rα (CD25) Inhibitor Therapies in GVHD
  • Table 30: Product Profile - Biologics - Co-Stimulatory Blockers
  • Table 31: Efficacy of Co-Stimulatory Blocker Therapies in GVHD
  • Table 32: Product Profile - Other Biologics (Campath/Lemtrada and Rituxan)
  • Table 33: Efficacy of Other Biologic Therapies (Campath/Lemtrada and Rituxan) in GVHD
  • Table 34: Safety Profile - Off-Label Biologics Used in GVHD, 2014
  • Table 35: SWOT Analysis - Biologics - TNFα Inhibitors, 2014
  • Table 36: SWOT Analysis - Biologics - IL-2Rα (CD25) inhibitors, 2014
  • Table 37: SWOT Analysis - Biologics - Co-Stimulatory Blockers, 2014
  • Table 38: SWOT Analysis - Biologics - Others, 2014
  • Table 39: Product Profile - Small Immunosuppressive Molecules - mTOR Inhibitors
  • Table 40: Efficacy of mTOR Inhibitors in GVHD
  • Table 41: Product Profile - Small Immunosuppressive Molecules - SOT Therapies
  • Table 42: Efficacy of SOT Therapies in GVHD
  • Table 43: Product Profile - Small Immunosuppressive Molecules - Anti-Neoplastic Therapies
  • Table 44: Efficacy of Anti-Neoplastic Therapies in GVHD
  • Table 45: Safety Profile - Small Immunosuppressive Molecules
  • Table 46: SWOT Analysis - Small Immunosuppressive Molecules - mTOR Inhibitors, 2014
  • Table 47: SWOT Analysis - Small Immunosuppressive Molecules - SOT Therapies, 2014
  • Table 48: SWOT analysis - Small Immunosuppressive Molecules - Anti-Neoplastic Therapies, 2014
  • Table 49: Unmet Need and Opportunity in GVHD
  • Table 50: Clinical Trial Design of Key Pipeline Drugs for GVHD, July 2014
  • Table 51: GVHD - Late Stage Pipeline, 2013
  • Table 52: Product Profile - Leukotac (inolimomab)
  • Table 53: Efficacy of Leukotac in GVHD
  • Table 54: SWOT Analysis - Leukotac (inolimomab), 2014
  • Table 55: Product Profile - Begedina (BT 5/9)
  • Table 56: Efficacy of Begedina in GVHD
  • Table 57: SWOT Analysis - Begedina (BT 5/9), 2015
  • Table 58: Product Profile - Budenofalk (budesonide)
  • Table 59: SWOT Analysis - Budenofalk, 2014
  • Table 60: Product Profile - ATG-Fresenius (EZ-2053)
  • Table 61: Efficacy of ATG-Fresenius in GVHD (EZ-2053)
  • Table 62: SWOT Analysis - ATG-Fresenius, 2014
  • Table 63: Product Profile - Prochymal (remestemcel-L)
  • Table 64: SWOT Analysis - Prochymal (remestemcel-L), 2014
  • Table 65: Product Profile - MultiStem (modified mesenchymal stem cells)
  • Table 66: SWOT Analysis - MultiStem (modified mesenchymal stem cells)
  • Table 67: Product Profile - Uvadex (Extracorporeal Photophoresis)
  • Table 68: Efficacy of Uvadex in GVHD
  • Table 69: SWOT Analysis - Uvadex (Extracorporeal Photophoresis)
  • Table 70: Product Profile - orBec (beclomethasone dipropionate)
  • Table 71: SWOT Analysis - orBec (beclomethasone proprionate), 2014
  • Table 72: Early-Stage Pipeline Products for GVHD, July 2014
  • Table 73: Clinical Benchmarking for GVHD Prophylaxis, 2014
  • Table 74: Clinical Benchmarking for aGVHD, 2014
  • Table 75: Clinical Benchmarking for cGVHD, 2014
  • Table 76: Commercial Benchmarking for GVHD Prophylaxis, 2014
  • Table 77: Commercial Benchmarking for aGVHD, 2014
  • Table 78: Commercial Benchmarking for cGVHD, 2014
  • Table 79: Top-Line Sales Forecasts ($m) for GVHD, 2013-2023
  • Table 80: Key Events Impacting Sales for GVHD, 2013-2023
  • Table 81: Global GVHD Market - Drivers and Barriers, 2013-2023
  • Table 82: Key Launch Dates, GVHD, 2013-2023
  • Table 83: Key Patent Expiries, GVHD, 2013-2023

List of Figures

  • Figure 1: Schematic of HSCT
  • Figure 2: Schematic Flow Chart of the Derivation of the aGVHD and cGVHD Patient Population in the 6MM
  • Figure 3: 6MM, Diagnosed Incident Cases of HSCTs , Both Sexes, All Ages, N, 2013-2023
  • Figure 4: 6MM, Diagnosed Incident Cases of Autologous HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Figure 5: 6MM, Diagnosed Incident Cases of Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Figure 6: 6MM, Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Figure 7: 6MM, Four-Year Diagnosed Prevalent Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, 2013-2023
  • Figure 8: 6MM, Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023
  • Figure 9: 6MM, Five-Year Diagnosed Prevalent Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023
  • Figure 10: Trends in aGVHD Management in the 6MM, 2014
  • Figure 11: Trends in cGVHD Management in the 6MM, 2014
  • Figure 12: Schematic Representation of Unmet Needs
  • Figure 13: An Overview of the GVHD Prophylaxis Clinical Trials, 2015
  • Figure 14: An Overview of the aGVHD Clinical Trials, 2015
  • Figure 15: An Overview of the cGVHD Clinical Trials, 2015
  • Figure 16: Competitive Assessment of GVHD Prophylaxis Off-Label Therapies and Late-Stage Pipeline Agents, 2013-2023
  • Figure 17: Competitive Assessment of aGVHD Off-Label Therapies and Late-Stage Pipeline Agents, 2013-2023
  • Figure 18: Competitive Assessment of cGVHD Off-Label Therapies and Late-Stage Pipeline Agents, 2013-2023
  • Figure 19: Global Sales for GVHD by Region and GVHD Indication, 2013-2023
Back to Top